CN101454328A - 新的mch受体拮抗剂 - Google Patents

新的mch受体拮抗剂 Download PDF

Info

Publication number
CN101454328A
CN101454328A CNA2007800195489A CN200780019548A CN101454328A CN 101454328 A CN101454328 A CN 101454328A CN A2007800195489 A CNA2007800195489 A CN A2007800195489A CN 200780019548 A CN200780019548 A CN 200780019548A CN 101454328 A CN101454328 A CN 101454328A
Authority
CN
China
Prior art keywords
phenyl
thieno
chloro
pyridin
methoxyl group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2007800195489A
Other languages
English (en)
Chinese (zh)
Inventor
M·B·阿诺尔德
Y·道
K·M·伽丁尼尔
D·J·加尔门
S·J·格林
E·J·亨布雷
陆建良
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of CN101454328A publication Critical patent/CN101454328A/zh
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CNA2007800195489A 2006-06-08 2007-06-08 新的mch受体拮抗剂 Pending CN101454328A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US81184106P 2006-06-08 2006-06-08
US60/811,841 2006-06-08

Publications (1)

Publication Number Publication Date
CN101454328A true CN101454328A (zh) 2009-06-10

Family

ID=38651254

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2007800195489A Pending CN101454328A (zh) 2006-06-08 2007-06-08 新的mch受体拮抗剂

Country Status (10)

Country Link
US (2) US8263772B2 (https=)
EP (1) EP2029609A2 (https=)
JP (1) JP5198439B2 (https=)
CN (1) CN101454328A (https=)
AU (1) AU2007257922A1 (https=)
BR (1) BRPI0712680A2 (https=)
CA (1) CA2652385A1 (https=)
EA (1) EA015127B1 (https=)
MX (1) MX2008015662A (https=)
WO (1) WO2007146758A2 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114286818A (zh) * 2019-07-02 2022-04-05 诺维逊生物股份有限公司 作为bet抑制剂的杂环化合物

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2740193A1 (en) 2008-12-23 2010-07-01 Abbott Laboratories Anti-viral compounds
EP2367823A1 (en) 2008-12-23 2011-09-28 Abbott Laboratories Anti-viral compounds
BRPI0923527A2 (pt) * 2008-12-24 2016-08-09 Syngenta Ltd métodos de preparo de fungicidas
CN102459165B (zh) * 2009-04-15 2015-09-02 Abbvie公司 抗病毒化合物
US8937150B2 (en) 2009-06-11 2015-01-20 Abbvie Inc. Anti-viral compounds
US9394279B2 (en) 2009-06-11 2016-07-19 Abbvie Inc. Anti-viral compounds
UA118080C2 (uk) 2009-06-11 2018-11-26 Еббві Айрленд Анлімітед Компані Противірусні сполуки
US8716454B2 (en) 2009-06-11 2014-05-06 Abbvie Inc. Solid compositions
NZ605440A (en) 2010-06-10 2014-05-30 Abbvie Bahamas Ltd Solid compositions comprising an hcv inhibitor
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
US9034832B2 (en) 2011-12-29 2015-05-19 Abbvie Inc. Solid compositions
US20150065343A1 (en) 2012-04-02 2015-03-05 Basf Se Acrylamide compounds for combating invertebrate pests
BR112014027133A2 (pt) 2012-05-09 2017-06-27 Basf Se compostos, composição agrícola ou veterinária, método para o controle das pragas de invertebrados, material de propagação dos vegetais e método para o tratamento ou proteção de um animal.
MX394360B (es) 2013-03-14 2025-03-24 Sumitomo Pharma Oncology Inc Inhibidores de jak2 y alk2 y metodos para su uso.
US11484534B2 (en) 2013-03-14 2022-11-01 Abbvie Inc. Methods for treating HCV
EP3089757A1 (en) 2014-01-03 2016-11-09 AbbVie Inc. Solid antiviral dosage forms
AR102849A1 (es) * 2015-03-09 2017-03-29 Astellas Pharma Inc Compuesto de piridina bicíclica
ES2849951T3 (es) 2015-06-18 2021-08-24 89Bio Ltd Derivados de piperidina 4-bencil y 4-benzoil sustituidos
EA201890086A1 (ru) 2015-06-18 2018-06-29 Сефалон, Инк. 1,4-замещенные производные пиперидина
MX2021000977A (es) 2018-07-26 2021-04-12 Sumitomo Pharma Oncology Inc Metodos para tratar enfermedades asociadas con expresion anormal de receptor de activina a tipo 1 (acvr1) e inhibidores de acvr1 para uso en los mismos.
CN113226322A (zh) 2018-10-30 2021-08-06 诺维逊生物股份有限公司 作为bet抑制剂的杂环化合物
US20260028336A1 (en) * 2022-07-20 2026-01-29 Arcus Biosciences, Inc. Cbl-b inhibitors and methods of use thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002003370A (ja) * 1999-09-20 2002-01-09 Takeda Chem Ind Ltd メラニン凝集ホルモン拮抗剤
US20020099073A1 (en) * 2000-07-07 2002-07-25 Andersen Henrik Sune Modulators of protein tyrosine phosphatases (PTPases)
GB0124627D0 (en) * 2001-10-15 2001-12-05 Smithkline Beecham Plc Novel compounds
US20060194871A1 (en) * 2003-04-11 2006-08-31 Barvian Kevin K Heterocyclic mchr1 antagoists
US20070078125A1 (en) * 2003-10-23 2007-04-05 Glaxo Group Limited Arylamine mch r1 antagonists
WO2005047293A1 (en) * 2003-11-07 2005-05-26 Neurocrine Biosciences, Inc. Melanin-concentrating hormone receptor antagonists and compositions and methods related thereto
UA83416C2 (en) * 2004-02-13 2008-07-10 Баниу Фармасьютикал Ко., Лтд. Fused ring 4-oxopyrimidine derivative
US20050256124A1 (en) * 2004-04-15 2005-11-17 Neurocrine Biosciences, Inc. Melanin-concentrating hormone receptor antagonists and compositions and methods related thereto
MXPA06014535A (es) 2004-06-18 2007-06-05 Biolipox Ab Indoles utiles en el tratamiento de la inflamacion.
US7902356B2 (en) * 2004-12-17 2011-03-08 Eli Lilly And Company Thiazolopyridinone derivates as MCH receptor antagonists
EP1987020B1 (en) * 2006-02-15 2012-10-03 Sanofi Azacyclyl-substituted aryldihydroisoquinolinones, process for their preparation and their use as medicaments
KR20080094699A (ko) * 2006-02-15 2008-10-23 사노피-아벤티스 신규 아미노알콜-치환된 아릴디하이드로이소퀴놀리논, 이의제조 방법 및 이의 약물로서의 용도

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114286818A (zh) * 2019-07-02 2022-04-05 诺维逊生物股份有限公司 作为bet抑制剂的杂环化合物

Also Published As

Publication number Publication date
US20090093456A1 (en) 2009-04-09
JP5198439B2 (ja) 2013-05-15
BRPI0712680A2 (pt) 2012-11-20
EP2029609A2 (en) 2009-03-04
WO2007146758A3 (en) 2008-02-07
EA200870517A1 (ru) 2009-04-28
WO2007146758A2 (en) 2007-12-21
CA2652385A1 (en) 2007-12-21
US8263772B2 (en) 2012-09-11
EA015127B1 (ru) 2011-06-30
JP2009539875A (ja) 2009-11-19
AU2007257922A1 (en) 2007-12-21
MX2008015662A (es) 2009-01-12
US20120302547A1 (en) 2012-11-29

Similar Documents

Publication Publication Date Title
CN101454328A (zh) 新的mch受体拮抗剂
US7812017B2 (en) 4-substituted indole and indoline compounds
JP4754821B2 (ja) 肥満症、ii型糖尿病およびcns障害の治療に有用な新規化合物
CN101426783B (zh) 作为11-β-羟基甾族化合物脱氢酶1的抑制剂的环己基吡唑-内酰胺衍生物
US6380238B1 (en) Indoline derivatives as 5-HT2B and or 5-HTC receptor ligands
US20110015185A1 (en) Benzofuran Compounds
TWI557110B (zh) 作為5-ht6拮抗劑的芳基磺醯基吡唑啉羧脒衍生物
WO2003062205A1 (en) 7-sulfonyl-3-benzazepine derivatives as modulators of the dopamine receptor and their use for the treatment of cns disorders
AU2008256859A1 (en) 4' substituted compounds having 5-HT6 receptor affinity
JP2009507037A (ja) 5−HT2C受容体アゴニストとしての6−置換された2,3,4,5−テトラヒドロ−1H−ベンゾ[d]アゼピン
JP2024028642A (ja) カンナビノイド受容体部分アゴニストとしてのインダゾール誘導体
CN101321765A (zh) 可用作vr1受体拮抗剂的苯并吡喃酮衍生物
CN104884436B (zh) 苯并氮杂衍生物及其医药用途
TW201116531A (en) Ring-annulated dihydropyrrolo[2,1-a]isoquinolines
JP2017525734A (ja) 癌の治療において有用なイソキノリノン誘導体
CN119790048A (zh) 新颖的取代的四氢异喹啉-6-甲酸衍生物、用于其制备的方法及其治疗用途
JP2025526986A (ja) 新規な置換ベンゾチオフェン-6-カルボン酸誘導体、その調製方法、及びその治療的使用
CN100522161C (zh) 作为大麻素cb1受体的激动剂的(吲哚-3-基)-杂环衍生物
KR20260035942A (ko) 만성 통증 치료를 위한 gpr183 길항제로서의 2-페녹시-1-(4-(알킬설포닐)피페리딘-1-일)에탄-1-온 및 3-페닐-1-(4-(알킬설포닐)피페리딘-1-일)프로프-2-엔-1-온 유도체

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
AD01 Patent right deemed abandoned

Effective date of abandoning: 20090610

C20 Patent right or utility model deemed to be abandoned or is abandoned